<DOC>
	<DOCNO>NCT00759109</DOCNO>
	<brief_summary>This study aim compare role peginterferon α-2b ( 50 μg/week ) vs. control ( treatment ) prevention hepatocellular carcinoma , adult patient cirrhosis initial sign portal hypertension respond previous combine therapy interferon alfa + ribavirin peginterferon alfa + ribavirin interferon alfa monotherapy high proliferation rate enter study . The duration treatment 3 year , follow-up period 2 year .</brief_summary>
	<brief_title>Pegylated Alfa-2b Interferon Therapy Patients With Hepatitis C-related Cirrhosis High Liver Cell Proliferation ( P02733/MK-4031-085 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Cirrhotic participant , sex , Child Pugh A , B , HCVRNA positive , age &lt; 70 year Participants nonresponders IFN + Ribavirin PegIFN + Ribavirin IFN monotherapy Pretherapy liver biopsy ( &lt; 36 month ) PCNALI &gt; 2.0 Fibrosis score 56 ( Ishak ) Initial portal hypertension , gastroesophageal varix one follow US sign : Collateral circle Spleen longitudinal diameter &gt; 12 cm Portal vein diameter hilus &gt; 12 mm Portal flow &gt; 12 cm/sec Participants must follow minimum hematologic biochemical criterion : Hemoglobin &gt; = 11 g/dL Granulocyte count &gt; 1,000/mm^3 Platelets &gt; 70,000/mm^3 Prothrombin activity &gt; 50 % Total bilirubin &lt; 3 mg/dL Albumin &gt; = 3.5 g/dL Serum creatinine within normal limit Uric Acid within normal limit Thyroid Stimulating Hormone ( TSH ) , within normal limit Antinuclear antibody ( ANA ) &lt; 1:160 Written inform consent Women childbearing potential must negative pregnancy test Acceptance patient sex proper contraceptive measure study period Pregnant breastfeed woman Coinfection HIV and/or HBV Autoimmune hepatitis history autoimmune disease Alcoholic liver disease Metabolic disease HCC Participants liver kidney transplant Evidence decompensated liver disease history presence ascites , bleed varix , spontaneous encephalopathy Chronic renal failure creatinine clearance &lt; 50 mL/min Preexisting thyroid disease unless controlled conventional treatment History presence psychiatric condition , especially depression , history severe psychiatric disorder , major psychosis , suicidal ideation and/or suicidal attempt Epilepsy and/or compromise central nervous system ( CNS ) function Significant cardiovascular dysfunction within previous 6 month study start ( eg , angina , congestive heart failure , recent myocardial infarction , moderate severe hypertension , significant arrhythmia ) Hemoglobinopathies Poorly control diabetes mellitus Chronic pulmonary disease ( eg , chronic obstructive pulmonary disease ) Clinical gout Hypersensitivity interferon component drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>